(HealthDay News) — For patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, the L858R mutation in circulating free DNA (cfDNA) seems to be a ...

EAI-432, an allosteric inhibitor, offers a new approach to targeting mutant-EGFR driven NSCLC By binding outside the ATP pocket, it co-binds with the current standard-of-care third generation EGFR ...

The influence of ER on small HER2-positive invasive breast cancers. Background: Mutations in the tyrosine kinase (TK) domain of EGFR have been associated with clinical benefit from EGFR TK inhibitors.

Treatment pattern and outcomes in patients with uncommon or compound EGFR mutations in India: CRSF 2020-03 study. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract ...

Credit: AstraZeneca. Tagrisso, a kinase inhibitor, is available as 40mg and 80mg strength tablets in 30-count bottles. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) in ...